[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.244.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
This Week in JAMA
November 15, 2006

This Week in JAMA

JAMA. 2006;296(19):2289. doi:10.1001/jama.296.19.2289

A JAMA THEME ISSUE

Edited by Phil B. Fontanarosa, MD, MBA, and Helene M. Cole, MD

Men with overactive bladder and other lower urinary tract symptoms are often treated with an antimuscarinic agent or an α-adrenergic receptor antagonist; however, monotherapy is not always effective. In a randomized 12-week trial, Kaplan and colleagues investigated the efficacy and safety of tolterodine extended release (an antimuscarinic), tamsulosin (an α-adrenergic receptor antagonist), both drugs, or placebo in men with overactive bladder and benign prostatic hypertrophy. The authors found that men who received combination therapy were significantly more likely to report treatment benefit than men receiving either monotherapy or placebo. All active treatments were well tolerated and the incidence of acute urinary retention was low.

×